<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2503245085
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MEGAMOX ES 600 mg powder for oral suspension
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMOXICILLIN,CLAVULANIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500,42.9
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01CR02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong>Megamox- Extra Strength (ES) is an antibiotic and works by killing bacteria that cause infections. It contains two different medicines called amoxicillin and clavulanic acid. Amoxicillin belongs to a group of medicines called &ldquo;penicillins&rdquo; that can sometimes be stopped from working (made inactive). The other active component (clavulanic acid) stops this from happening.</p><p>Megamox-ES is used in babies and children to treat the with recurrent or persistent acute otitis media.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Megamox-ES</p><ul><li>if they are allergic (hypersensitive) to amoxicillin, clavulanic acid or any of the other ingredients of Megamox-ES (listed in section 6)</li><li>if they have ever had an allergic (hypersensitive) reaction to any other antibiotic.</li></ul><p>This can include a skin rash or swelling of the face or neck</p><ul><li>if they have ever had liver problems or jaundice (yellowing of the skin) when taking an antibiotic.</li><li>Do not give Megamox-ES to your child if any of the above apply to your child.</li></ul><p>If you are not sure, talk to their doctor or pharmacist before giving Megamox-ES.</p><p>Take special care with Megamox-ES</p><p>Check with their doctor or pharmacist before giving your child this medicine if they:</p><ul><li>have glandular fever</li><li>are being treated for liver or kidney problems</li><li>are not passing water regularly.</li></ul><p>If you are not sure if any of the above apply to your child, talk to their doctor or pharmacist before giving Megamox-ES. In some cases, your doctor may investigate the type of bacteria that is causing your child&rsquo;s infection. Depending on the results, your child may be given a different strength of Megamox-ES or a different medicine.</p><p>Conditions you need to look out for Megamox-ES can make some existing conditions worse, or cause serious side effects.</p><p>These include allergic reactions, convulsions (fits) and inflammation of the large intestine. You must look out for certain symptoms while your child is taking Megamox-ES, to reduce the risk of any problems. See &lsquo;Conditions you need to look out for&rsquo; in section 4.</p><p><strong>Blood or urine tests</strong></p><p>If your child is having blood tests (such as red blood cell status tests or liver function tests) or urine tests, let the doctor or nurse know that they are taking Megamox-ES. This is because Megamox-ES can affect the results of these types of tests.</p><p><strong>Using other medicines</strong></p><p>Please tell your doctor or pharmacist if your child is taking or has recently taken any other medicines. This includes medicines that can be bought without a prescription and herbal medicines.</p><p>If your child is taking allopurinol (used for gout) with Megamox-ES, it may be more likely that they will have an allergic skin reaction.</p><p>If your child is taking probenecid (used for gout), your doctor may decide to adjust the dose of Megamox-ES.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If your child who is about to take this medicine is pregnant or breast-feeding, please tell your doctor or pharmacist.</p><p><strong>Ask your doctor or pharmacist for advice before taking any medicine.</strong></p><p>Important information about some of the ingredients of Megamox-ES</p><ul><li>Megamox-ES contains aspartame (E951) which is a source of phenylalanine. This may be harmful for children born with a condition called &rsquo;phenylketonuria&rsquo;.</li><li>Megamox-ES contains maltodextrin (glucose). If you have been told by your doctor that your child has an intolerance to some sugars, contact your doctor before taking this medicinal product.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="docshape8" o:spid="_x0000_s1026" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:101.15pt;
 margin-top:16.4pt;width:143.55pt;height:47.2pt;z-index:15735808;
 mso-position-horizontal-relative:page' filled="f" strokeweight="1pt">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><p>Always give Megamox-ES exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Adults and children weighing 40 kg or over</p><ul><li>This suspension is not usually recommended for adults and children weighing 40 kg and over. Ask your doctor or pharmacist for advice.</li></ul><p>Children patients 3 months and older and weighing less than 40 kg</p><p>All doses are worked out depending on the child&rsquo;s body- weight in kilograms.</p><ul><li>Your doctor will advise you how much Megamox-ES you should give to your baby or child.</li><li>You may be provided with a plastic measuring spoon or measuring cup. You should use this to give the correct dose to your baby or child.</li><li>Usual dose - 90 mg(Amoxicillin)/6.4 mg(Clavulanic acid) for each kilogram of body weight a day, given in two divided doses administered for 10 days.</li></ul><p><strong>Patients with kidney and liver problems</strong></p><ul><li>If your child has kidney problems the dose might be lowered. A different strength or a different medicine may be chosen by your doctor.</li><li>If your child has liver problems they may have more frequent blood tests to see how their liver is working.</li></ul><p><strong>How to give Megamox-ES</strong></p><p>Instruction for mixing:</p><ul><li>After opening the bottle remove the membrane care- fully and completely and discard before reconstituting the product. Fill the bottle with water to just below the mark on the label and shake well at once. Then add water exactly to the mark and shake vigorously again.</li><li>Always shake the bottle well before each dose</li><li>Give at the start of a meal or slightly before</li><li>Do not give your child Megamox-ES for more than 2 weeks. If your child still feels unwell they should go back to see the doctor.</li></ul><p>If you give more Megamox-ES than you should</p><p>If you give your child has too much Megamox-ES, signs might include an upset stomach (feeling sick, being sick or diarrhoea) or convulsions . Talk to their doctor as soon as possible. Take the medicine bottle to show the doctor.</p><p>If you forget to give Megamox-ES</p><p>If you forget to give your child a dose, give it as soon as you remember. You should not give your child the next dose too soon, but wait about 8 hours before giving the next dose.</p><p>If your child stops taking Megamox-ES</p><p>Keep giving your child Megamox-ES until the treatment is finished, even if they feel better. Your child needs every dose to help fight the infection. If some bacteria survive they can cause the infection to come back.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Megamox-ES can cause side effects, although not everybody gets them. The side effects below may happen with this medicine.</p><p>Conditions you need to look out for</p><p><strong>Allergic reactions:</strong></p><ul><li>skin rash</li><li>inflammation of blood vessels (vasculitis) which may be visible as red or purple raised spots on the skin, but can affect other parts of the body</li><li>fever, joint pain, swollen glands in the neck, armpit or groin</li><li>swelling, sometimes of the face or mouth (angioedema), causing difficulty in breathing</li><li>collapse.</li><li>Contact a doctor immediately if your child gets any of these symptoms. Stop taking Megamox-ES.</li></ul><p>Inflammation of large intestine</p><p>Inflammation of the large intestine, causing watery diarrhoea usually with blood and mucus, stomach pain and/or fever.</p><ul><li>Contact your doctor as soon as possible for advice if your child gets these symptoms.</li></ul><p><strong>Other possible side effects:</strong></p><p>Very common side effects ( affect more than 1 in 10 people)</p><ul><li>diarrhoea (in adults).</li></ul><p>Common side effects (affects 1 to 10 patients in 100) include:</p><ul><li>thrush (candida - a yeast infection of the vagina, mouth or skin folds)</li><li>feeling sick (nausea), especially when taking high doses</li><li>if affected take Megamox-ES before food</li><li>vomiting</li><li>diarrhoea (in children).</li></ul><p>Uncommon side effects (affects 1 to 10 patients in 1,000) include:</p><ul><li>skin rash, itching</li><li>raised itchy rash (hives)</li><li>indigestion</li><li>dizziness</li><li>headache.</li></ul><p>Uncommon side effects that may show up in blood tests:</p><ul><li>increase in some substances (enzymes) produced by the liver</li></ul><p>Rare side effects (affects 1 to 10 patients in 10,000) include:</p><p>These may affect up to 1 in 1000 people</p><ul><li>skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge - erythema multiforme)</li><li>if you notice any of these symptoms contact a doctor urgently.</li></ul><p>Rare side effects that may show up in blood tests:</p><ul><li>low number of cells involved in blood clotting</li><li>low number of white blood cells.</li></ul><p><strong>Other side effects</strong></p><p>Other side effects have occurred in a very small number of people but their exact frequency is unknown.</p><ul><li>Allergic reactions (see above)</li><li>Inflammation of the large intestine (see above)</li><li>Inflammation of the protective membrane surrounding the brain (aseptic meningitis)</li><li>Serious skin reactions:</li></ul><p>- a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), and a more severe form, causing extensive peeling of the skin (more than 30% of the body surface - toxic epidermal necrolysis)</p><p>- widespread red skin rash with small pus-containing blisters (bullous exfoliative dermatitis)</p><p>- a red, scaly rash with bumps under the skin and blisters (exanthemous pustulosis).</p><p>Contact a doctor immediately if your child gets any of these symptoms.</p><ul><li>inflammation of the liver (hepatitis)</li><li>jaundice, caused by increases in the blood of bilirubin (a substance produced in the liver) which may make your child&rsquo;s skin and whites of the eyes appear yellow</li><li>inflammation of tubes in the kidney</li><li>blood takes longer to clot</li><li>hyperactivity</li><li>convulsions (in people taking high doses of Megamox-ES or who have kidney problems)</li><li>black tongue which looks hairy</li><li>stained teeth (in children), usually removed by brushing.</li></ul><p><strong>Side effects that may show up in blood or urine tests:</strong></p><ul><li>severe reduction in the number of white blood cells</li><li>low number of red blood cells (haemolytic anaemia)</li><li>crystals in urine.</li></ul><p><strong>If your child gets side effects</strong></p><p>Tell your doctor or pharmacist if any of the side effects become severe or troublesome, or if you notice any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach and sight of children.</li><li>Store below 30&deg;C.</li><li>Do not use Megamox-ES after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</li><li>After made up your medicine. It should be used within 10 days. Store in the fridge, but do not freeze.</li><li>If your medicine becomes discoloured or show any other signs of deterioration, ask your pharmacist who will advise you what to do.</li><li>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Megamox-ES Suspension contain</p><p>The active substances are 600 mg amoxicillin and 42.9 mg clavulanic acid (present as potassium clavulanate) in every 5 ml of suspension</p><p>The other ingredients are: Xanthan Gum ; Succinic Acid micronized; Colloidal Silicon Dioxide; Predried nutra sweet- aspartam treated; Predried hydroxypropyl methyl cellulose; Orange Powder Flavor; Predried Silicon Dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Megamox-ES 600 mg;42.9 mg /5 ml suspension is white to off-white powder, after reconstitution give off-white suspension with orange flavor.

Pack size: Bottle of 100 ml of suspension after reconstitution.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jazeera Pharmaceutical Industries (JPI)</p><p>Riyadh, Saudi Arabia, 11666 Riyadh, P.O.Box 106229</p><p>Telephone No.: +966-11-207-8172</p><p>Fax: +966-11-207-8097</p><p>Email: medical@jpi.com.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 01/2014, version 1.1 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;ميجاموكس-إي اس هومضاد حيوي ويعمل عن طريق قتل البكتيريا التي تسبب الالتهابات. يحتوي على اثنين من الأدوية المختلفة يدعى أحدهما أموكسيسيلين والأخر حمض الكلافولانيك. أموكسيسيلين ينتمي إلى مجموعة من الأدوية تسمى &laquo;البنسلين&raquo; التي يمكن في بعض الأحيان أن تتوقف عن العمل (غير نشطه). لكن بوجود العنصر النشط الأخر (حمض الكلافولانيك) يعمل على منع الاموكسيسيلين من التوقف.</p><p dir="RTL">يستخدم ميجاموكس-إي اس لدى الرضع والأطفال لعلاج التهابات الأذن الوسطى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;موانع استعمال ميجاموكس-إي اس</p><ul dir="rtl"><li>إذا كانت لديهم حساسية (الحساسية) لأموكسيسيلين، حمض الكلافولانيك أو أي من المكونات الأخرى من ميجاموكس-إي اس (المدرجة في القسم 6)</li><li>&nbsp;إذا كان لديهم أي وقت مضى الحساسية (فرط الحساسية) رد فعل على أي من المضادات الحيوية الأخرى.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;هذا ويمكن أن تشمل طفح جلدي أو تورم في الوجه أو الرقبة</li><li>إذا كان لديهم أي وقت مضى مشاكل في الكبد أو اليرقان (اصفرار الجلد) عندما استخدام أي من المضادات الحيوية.</li><li>لا تعطي ميجاموكس-إي اس لطفلك إذا كان أي من الأسباب أعلاه مرافقه له. إذا كنت غير متأكد، تحدث إلى الطبيب أو الصيدلي قبل إعطاء ميجاموكس-إي اس .</li></ul><p dir="RTL"><strong>الاحتياطات عند استعمال ميجاموكس-إي اس</strong></p><p dir="RTL">تحقق مع الطبيب أو الصيدلي قبل اعطاء طفلك هذا الدواء إذا كانت</p><ul dir="rtl"><li>لديك الحمى الغدية</li><li>تتعالج من مشاكل في الكبد أو الكلى</li><li>لا تشرب المياه بانتظام&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p dir="RTL">&nbsp;إذا لم تكن متأكدا مما إذا كان أي من أعلاه تنطبق على طفلك، تحدث إلى الطبيب أو الصيدلي قبل إعطاء ميجاموكس-إي اس .</p><p dir="RTL">في بعض الحالات، قد يتمكن&nbsp;&nbsp; طبيبك من معرفة نوع البكتيريا المسببة للعدوى لطفلك. اعتمادا على هذه النتائج، يمكن إعطاء طفلك تركيز مختلف من ميجاموكس-إي اس أو دواء اخر.</p><p dir="RTL">بعض الحالات المرضية ينبغي مراقبتها اذا تزامنت مع استعمال ميجاموكس-إي اس مما قد يزيد سوء تلك الحالة، أو يتسبب في آثار جانبية خطيرة.</p><p dir="RTL">وتشمل هذه الحالات المرضية: الحساسية، التشنجات (النوبات) والتهاب الأمعاء الغليظة. يجب أن نبحث عنها لبعض الأعراض في حين أن طفلك يأخذ ميجاموكس إي اس ، للحد من خطر أي مشاكل. انظر &quot; حالات مرضية ينبغي توخي الحذر لها في القسم 4&quot;</p><p dir="RTL"><strong>&nbsp;فحوصات الدم أو البول </strong></p><p dir="RTL">إذا قام طفلك بفحوصات الدم (مثل اختبارات خلايا الدم الحمراء خلية أو فحوصات وظائف الكبد) أو فحوصات البول، أخبر الطبيب أو الممرضة ما اذا كان طفلك يستعمل ميجاموكس-إي اس.</p><p dir="RTL">وذلك لأن ميجاموكس-إي اس يمكن أن تؤثر على نتائج هذه الأنواع من الفحوصات. التداخلات الدوائية من اخذ هذا المستحضر مع أي أدوية أخرى او اعشاب او مكملات غذائية</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كان طفلك يأخذ أو اخذ مؤخرا أي أدوية أخرى. وهذا يشمل الأدوية التي يمكن شراؤها دون وصفة طبية والأدوية العشبية.</p><p dir="RTL">إذا كان طفلك يأخذ الوبيورينول (يستخدم لمرض النقرس) مع ميجاموكس-إي اس ، قد يكون من الأرجح أن يكون لديهم رد فعل حساسية الجلد</p><p dir="RTL">&nbsp;إذا كان طفلك يأخذ البروبينسيد ( يستخدم لمرض النقرس)، طبيبك قد يقرر بتعديل جرعة من ميجاموكس-إي اس.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كانت طفلتك التي هي على وشك استعمال هذا الدواء حاملا او مرضعا رضاعة الطبيعية، يرجى إخبار الطبيب أو الصيدلي.</p><p dir="RTL">إسأل طبيبك أو الصيدلي للحصول على المشورة قبل اتخاذ أي دواء</p><p dir="RTL"><strong>&nbsp;معلومات هامة حول بعض مكونات ميجاموكس-إي اس</strong></p><ul dir="rtl"><li>يحتوي ميجاموكس-إي اس الأسبارتيم (E951) والذي هو مصدر للفينيلألانين. وهذا قد يكون ضارا للأطفال المولودين مع حالة تسمى &laquo;الفينيلكيتون يوريا.</li><li>يحتوي ميجاموكس-إي اس على (الجلوكوز). إذا كنت قد قال من قبل الطبيب بأن طفلك لديه التعصب لبعض السكريات، اتصل بطبيبك قبل أخذ هذا المنتج الطبية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;دائما تعطي ميجاموكس- إي اس تماما كما وصفه طبيبك لك. يجب عليك التحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL"><strong>البالغين والأطفال ممن يزنون 40 كجم أو أكثر</strong></p><ul dir="rtl"><li>لا ينصح باستعمال هذا المعلق عادة للبالغين والأطفال ممن اوزنهم تساوي 40 كجم أو أكثر. إسأل طبيبك أو الصيدلي للحصول على المشورة.</li></ul><p dir="RTL">الأطفال من سن الثلاثة اشهر واكبر ممن تقل اوزانهم عن 40 كجم تم ضبط جميع الجرعات اعتمادا على وزن جسم الطفل بالكيلوغرام.</p><ul dir="rtl"><li>سوف يقوم طبيبك بجرعة ميجاموكس-إي اس التي يجب أن تعطي لطفلك.</li><li>تزود علبة الدواء بملعقة بلاستيكية للقياس أو كوب القياس. يجب عليك استخدامه لإعطاء الجرعة الصحيحة لطفلك.</li><li>الجرعة المعتادة - ۹۰ ملغ ( أموكسيسيلين)/6,4 ملغ ( حمض كلافولانيك) لكل كيلوغرام من وزن الجسم ، تعطى كل ۱۲ ساعه يوميا لمدة عشرة أيام.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; المرضى الذين يعانون من مشاكل في الكلى والكبد</li><li>إذا كان طفلك يعاني من مشاكل في الكلى يمكن خفض الجرعة. او إعطاء تركيز مختلف أو دواء اخر يمكن اختياره من قبل الطبيب.</li><li>إذا كان طفلك لديه مشاكل في الكبد قد بفحوصات الدم أكثر تواترا لمعرفة كيفية عمل الكبد.</li></ul><p dir="RTL"><strong>كيفية إعطاء ميجاموكس-إي اس</strong></p><ul dir="rtl"><li>طريقة عمل المحلول: املأ الزجاجة بالماء لأسفل العلامة الظاهرة على العبوة ويرج جيدا. ثم تكمل اضافة الماء بالضبط إلى العلامة الظاهرة على العبوة و يرج بقوة مره اخرى.</li><li>قم برج الزجاجة جيدا قبل كل جرعة</li><li>يعطى في بداية الوجبة أو قبلها بقليل</li><li>&nbsp;لا تعطي طفلك ميجاموكس-إي اس لأكثر من اسبوعين. إذا كان لا يزال يشعر بتوعك طفلك يجب أن تنعود لرؤية الطبيب.</li></ul><p dir="RTL"><strong>الجرعة الزائدة من ميجاموكس- إي اس</strong></p><p dir="RTL">إذا كنت تناول طفلك الكثير من ميجاموكس-إي اس ، قد تشمل العلامات اضطراب في المعدة ( الشعور بالغثيان، أو الإسهال) أو التشنجات. تحدث الى الطبيب في أقرب وقت ممكن. خذ زجاجة الدواء لإظهارها للطبيب.</p><p dir="RTL"><strong>نسيان تناول جرعة ميجاموكس- إي اس</strong></p><p dir="RTL">إذا نسيت اعطاء طفلك جرعة، قم بإعطائها في أقرب وقت تتذكر. يجب أن لا تعطي طفلك الجرعة التالية قريبا جدا، ولكن الانتظار قبل إعطاء الجرعة التالية حوالي ۸ ساعات.</p><p dir="RTL"><strong>التوقف عن تناول ميجاموكس-إي اس</strong></p><p dir="RTL">استمر بإعطاء طفلك ميجاموكس-إي اس حتى يتم الانتهاء من العلاج، حتى لو كانوا يشعرون بالتحسن. يحتاج طفلك كل جرعة للمساعدة في مكافحة العدوى. إذا بقيت بعض أنواع البكتيريا على قيد الحياة قد تمكن من معاودة العدوى مرة اخرى.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ،&nbsp;يمكن أن تتسبب في اعراض جانبية ميجاموكس - إي اس ، وإن لم تحصل للجميع. الآثار الجانبية أدناه قد تحدث مع هذا الدواء.</p><p dir="RTL"><strong>حالات مرضية ينبغي توخي الحذر لها</strong></p><p dir="RTL"><strong>الحساسية:</strong></p><ul dir="rtl"><li>طفح جلدي</li><li>التهاب الأوعية الدموية (فاسكيولايتس) والتي قد تكون مرئية على شكل بقع حمراء أو أرجوانية على الجلد، ولكن يمكن أن تؤثر على أجزاء أخرى من الجسم</li><li>الحمى، وآلام المفاصل، وتورم الغدد في الرقبة، الإبط أو الفخذ</li><li>تورم، وأحيانا في الوجه أو الفم (وذمة وعائية)، مما تسبب صعوبة في التنفس</li><li>الانهيار.</li><li>اتصل بالطبيب فورا عند حصول أي من الأعراض اعلاه. و توقف عن تناول ميجاموكس-إي اس</li></ul><p dir="RTL"><strong>التهاب الأمعاء الغليظة</strong></p><p dir="RTL">التهاب الأمعاء الغليظة، مما يسبب الإسهال المائي عادة مع الدم والمخاط وآلام في المعدة و / أو حمى.</p><ul dir="rtl"><li>اتصل بطبيبك في أقرب وقت ممكن للحصول على المشورة إذا حصلت لطفلك هذه الأعراض.</li></ul><p dir="RTL">غيرها من الأعراض الجانبية المحتملة:</p><p dir="RTL">شائعة جدا ( تؤثر على 1 الى 10 من المستخدمين ):</p><ul dir="rtl"><li>الإسهال (في البالغين).</li></ul><p dir="RTL">شائعة ( تؤثر على 1 الى 10 من كل 100 من المستخدمين):</p><ul dir="rtl"><li>مرض القلاع (المبيضات - عدوى الخميرة في المهبل، الفم أو طيات الجلد)</li><li>&nbsp;الشعور بالغثيان (الغثيان، وخصوصا عندما تناول جرعات عالية إذا تأثرت استعمل ميجاموكس-إي اس قبل الطعام</li><li>&nbsp;القيء</li><li>الإسهال( عند الأطفال).</li></ul><p dir="RTL">غير شائعة ( تؤثر على 1 الى 10 من كل ۱،۰۰۰ من المستخدمين):</p><ul dir="rtl"><li>الطفح الجلدي، والحكة</li><li>أثار طفح حاك (خلايا النحل)</li><li>عسر الهضم</li><li>الدوخة</li><li>الصداع.</li></ul><p dir="RTL">الآثار الجانبية غير شائعة التي قد تظهر في فحوصات الدم:</p><ul dir="rtl"><li>الزيادة في بعض المواد ( الإنزيمات) التي ينتجها الكبد&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p dir="RTL">&nbsp; نادر (&nbsp; تؤثر&nbsp; على 1 الى 10 من كل ۱۰،۰۰۰ من المستخدمين):</p><p dir="RTL">قد تؤثر هذه تصل إلى 1 في ۱۰۰۰ شخص</p><ul dir="rtl"><li>طفح جلدي، والتي قد نفطة، ويبدو وكأنه الأهداف الصغيرة ( البقع السوداء المركزية وتحيط بها منطقة باهته، مع وجود حواف غامقة- التهاب جلدي حمامي عديد الأشكال)</li><li>إذا لاحظت أي من هذه الأعراض الاتصال الطبيب على وجه السرعة.</li></ul><p dir="RTL"><strong>الآثار الجانبية النادرة التي قد تظهر في فحوصات الدم:</strong></p><ul dir="rtl"><li>&nbsp;انخفاض عدد الخلايا المشاركة في تخثر الدم</li><li>انخفاض عدد خلايا الدم البيضاء.</li></ul><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p dir="RTL">حدثت اعراض جانبية أخرى في عدد صغير جدا من الناس ولكن وتيرتها الدقيقه غير معروفه.</p><ul dir="rtl"><li>الحساسية (انظر أعلاه)</li><li>التهاب الأمعاء الغليظة ( انظر أعلاه)</li><li>التهاب الغشاء الواقي الذي يحيط الدماغ (التهاب السحايا العقيم)</li><li>ردود فعل الجلد الشديد:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp;- طفح جلدي على نطاق واسع مع ظهور بثور وتقشير الجلد ، وبخاصة حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون)، وبشكل أكثر شدة، مما تسبب في تقشير واسعة من الجلد ( أكثر من ۳۰٪ من سطح الجسم - انحلال البشرة السام)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - طفح جلدي أحمر على نطاق واسع مع ظهور بثور تحتوي على صديد صغيرة ( التهاب الجلد التقشري الفقاعي)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - أحمرار، طفح متقشر مع المطبات تحت الجلد وظهور بثور ( بثاراكز انثمس).&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; اتصل بالطبيب فورا إذا حصل طفلك على أي من هذه الأعراض.</li><li>التهاب الكبد (هباتايتس)</li><li>اليرقان، والناجمة عن الزيادات في الدم من البيليروبين (مادة تنتج في الكبد) والتي قد تجعل جلد طفلك وبياض العينين تظهر صفراء اللون</li><li>التهاب الأنابيب في الكلى</li><li>يأخذ الدم وقتا أطول للتجلط</li><li>فرط النشاط</li><li>تشنجات (في الأشخاص الذين يتناولون جرعات عالية من ميجاموكس-إي اس أو الذين لديهم مشاكل في الكلى)</li><li>اللسان الأسود الذي يبدو شعر</li><li>تصبغ الأسنان (عند الأطفال)، تزال عادة عن طريق تنظيف الأسنان بالفرشاة.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; <strong>الآثار الجانبية التي قد تظهر في فحوصات الدم أو البول :</strong></li><li>انخفاض شديد في عدد خلايا الدم البيضاء</li><li>انخفاض عدد خلايا الدم الحمراء (فقر الدم الانحلالي)</li><li>البلورات في البول.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <strong>إذا حصلت لطفلك آثار جانبية&nbsp; </strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; أخبر طبيبك أو الصيدلي إذا كان أي من الآثار الجانبية الشديدة أو تصبح مزعجة، أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><ul><li>ابقي هذا المستحضر بعيدا عن متناول ايدي ونظر الأطفال.</li><li>&nbsp;يخزن في درجة حرارة لا تتجاوز ۳۰ درجة مئوية، ولكن بعد عمل المعلق يحفظ في الثلاجة لمدة لا تزيد عن. 10 ايام.</li><li>لاتستخدم ميجاموكس-إي اس بعد تاريخ انتهاء الصلاحية كما هو مدون على العبوة ، تاريخ الإنتهاء يشار اليه انه اليوم الأخير من ذلك الشهر.</li><li>إذا تغير لون الدواء او ظهرت عليه علامة اخرى من علامات التلف، اسأل الصيدلي الذي سوف ينصحك بما يجب القيام به.</li><li>لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي او النفايات المنزلية، اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتها ، وذلك لأن هذه التدابير تساعد في حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;يحتوي&nbsp;معلق الميجاموكس-إي اس على</p><p>المواد الفعالة هي 600 ملغ أموكسيسيلين و ۱۲٫۹ ملغ حمض الكلافولانيك ( على صورة كلافيولانيت البوتاسيوم) في كل 5 مل من المعلق</p><p>المكونات الأخرى هي: الصمغ زنتان؛ حمض السكسينك ميكرونيزد؛ صمغي ثاني أكسيد السيليكون، اسبارتيم المعالجة السليلوز هيدروكسي بروبيل ميثيل؛ مسحوق نكهة البرتقال، ثاني أكسيد السيليكون</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ماهو الشكل الصيدلاني لميجاموكس-إي اس ووصفه وحجم عبوته</strong></p><p>معلق الميجاموكس-إي اس 600 ملغ، ٤۲٫۹ ملغ / 5 ملهو بودرة بيضاء الى سكرية اللون، وبعد خلط المحلول نحصل على معلق سكري اللون بنكهة البرتقال</p><p>حجم العبوة: زجاجة 100 مل من المعلق بعد خلطه بالماء.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>الجزيرة للصناعات الدوائية (JPI)</p><p>الرياض، المملكة العربية السعودية، الرياض 11666، صندوق البريد ۱۰۹۲۲۹.</p><p>رقم الهاتف: ۸۱۷۲-۲۰۷-۱۱-۹۹۹+</p><p>فاكس: ۸۰۹۷-۲۰۷-۱۱-۹۹۹+</p><p>البريد الإلكتروني:medical@jpi.com.sa</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة الأخيرة في 01/2014 ,رقم النسخة ۱٫۱ 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Megamox® Extra Strength 600 mg /42.9 mg Powder for Oral Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml contains 600 mg amoxicillin and 42.9 mg Clavulanic acid.

For a full list of excipients, see sec on 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to off-white powder, after reconstitution white to off-white suspension with orange flavor.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Megamox ES-600 Powder for Oral Suspension is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to <em>S. pneumoniae </em>(penicillin MICs&nbsp;&nbsp;&nbsp; &le;&nbsp; &nbsp;2&nbsp; mcg/mL), <em>H.&nbsp;influenzae </em>(including &beta;-lactamase&ndash; producing,strains),or <em>M.catarrhalis </em>(including&beta;-lactamase&ndash;producingstrains) characterized by the following risk factors:</p><ul><li>an antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following:</li><li>age &le; 2 years</li><li>daycare attendance</li></ul><p><strong>NOTE: </strong>Acute otitis media due to <em>S. pneumoniae </em>alone can be treated with amoxicillin. MEGAMOX ES-600 Powder for Oral Suspension is not indicated for the treatment of acute otitis media due to <em>S. pneumoniae </em>with penicillin MIC &ge; 4 mcg/mL.</p><p>Therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both <em>S. pneumoniae </em>(penicillin MIC &le; 2 mcg/mL) and the &beta;-lactamase&ndash;producing organisms listed above.</p><p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of MEGAMOX ES-600 Powder for Oral Suspension and other an bacterial drugs, MEGAMOX ES-600 Powder for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.</p><p>When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>MEGAMOX ES 600 Powder for Oral Suspension, does not contain the same amount of clavulanic acid (as the potassium salt) as any of the other suspensions of MEGAMOX ES. MEGAMOX ES 600 Powder for Oral Suspension contains 42.9 mg of clavulanic acid per 5 mL, whereas the 200 mg/5 mL suspension of MEGAMOX ES contains 28.5 mg of clavulanic acid per 5 mL and the 400 mg/5 mL suspension contains 57 mg of clavulanic acid per 5 mL. Therefore, the 200 mg/28.5 mg/5 mL and 400 mg/57 mg/5 mL suspensions of MEGAMOX ES should <em>not </em>be substituted for MEGAMOX ES 600 Powder for Oral Suspension as they are not interchangeable.</p><p><strong>Dosage:</strong></p><p><strong><em>Pediatric pa ents 3 months and older: </em></strong>Based on the amoxicillin component (600 mg/5 mL,) the recommended dose of MEGAMOX ES 600 Powder for Oral Suspension is 90 mg/kg/day divided every 12 hours, administered for 10 days (see chart below).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:center"><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p style="text-align:center"><strong>Volume of MEGAMOX ES 600 Powder for Oral Suspension providing 90 mg/kg/day</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">8</p></td><td style="vertical-align:top"><p style="text-align:center">3.0 mL twice daily</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">12</p></td><td style="vertical-align:top"><p style="text-align:center">4.5 mL twice daily</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">16</p></td><td style="vertical-align:top"><p style="text-align:center">6.0 mL twice daily</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">20</p></td><td style="vertical-align:top"><p style="text-align:center">7.5 mL twice daily</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">24</p></td><td style="vertical-align:top"><p style="text-align:center">9.0 mL twice daily</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">28</p></td><td style="vertical-align:top"><p style="text-align:center">10.5 mL twice daily</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">32</p></td><td style="vertical-align:top"><p style="text-align:center">12.0 mL twice daily</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">36</p></td><td style="vertical-align:top"><p style="text-align:center">13.5 mL twice daily</p></td></tr></tbody></table><p><strong><em>Pediatric pa ents weighing 40 kg and more: </em></strong>Experience with MEGAMOX ES 600 Powder for Oral Suspension in this group is not available.</p><p><strong><em>Adults : </em></strong>Experience with MEGAMOX ES 600 Powder for Oral Suspension in adults is not available and adults who have difficulty swallowing should not be given MEGAMOX ES 600 Powder for Oral Suspension in place of the 500-mg or 875-mg tablet of MEGAMOX ES.</p><p><strong><em>Elderly: </em></strong>No dose adjustment is considered necessary.</p><p><strong><em>Renal impairment: </em></strong>No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 ml/min.</p><p>In patients with creatinine clearance less than 30 ml/min, the use of Megamox ES 400/57mg/5ml Powder for Oral Suspensionpresenta ons with an amoxicillin to clavulanic acid ra o of 7:1 is not recommended, as no recommenda ons for dose adjustments are available.</p><p><strong><em>Hepatic impairment: </em></strong>AUGMENTIN ES-600 Powder for Oral Suspension should be used with caution in patients with evidence of hepatic dysfunction. Hepatic toxicity associated with the use of amoxicillin/clavulanate potassium is usually reversible. On rare occasions, deaths have been reported (less than 1 death reported per es mated 4 million prescriptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications. (see sec on 4.3 and sec on 4.8).</p><p><strong><u>Method of administration</u></strong></p><p>Megamox ES 600/42.9mg/5ml Powder for Oral Suspension is for oral use.</p><p>Shake to loosen powder, add water as directed, invert and shake.</p><p>Shake the bo le before each dose (see sec on 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients.

History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).

History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid (see section 4.8).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents.</p><p>Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy must be discontinued and appropriate alternative therapy instituted.</p><p>In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.</p><p>This presentation of Megamox ES is not suitable for use when there is a high risk that the presumptive pathogens have reduced susceptibility or resistance to beta-lactam agents that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid (e.g. penicillin-insusceptible <em>S. pneumoniae</em>).</p><p>Convulsions may occur in patients with impaired renal function or in those receiving high doses (see sec on 4.8).</p><p>Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.</p><p>Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.</p><p>Prolonged use may occasionally result in overgrowth of non-susceptible organisms.</p><p>The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP) (see Sec on 4.8). This reac&nbsp;&nbsp; on requires Megamox ES discontinuation and contra- indicates any subsequent administration of amoxicillin.</p><p>Amoxicillin/clavulanic acid should be used with caution in patients with evidence of hepaticc impairment (see sec ons 4.2, 4.3 and 4.8).</p><p>Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children. In all populations, signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased. These are usually reversible. Hepatic events may be severe and, in extremely rare circumstances, deaths have been reported. These have almost always occurred in patients with serious underlying disease or taking concomitant medica ons known to have the poten al for hepa c eﬀects (see sec on 4.8).</p><p>Antibiotic-associated colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life threatening (see sec on 4.8). Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Should antibiotic-associated colitis occur, amoxicillin/clavulanic acid should immediately be discontinued, a physician be consulted and an appropriate therapy initiated. Anti-peristaltic medicinal products are contra-indicated in this situation.</p><p>Periodic assessment of organ system functions, including renal, hepatic and haematopoietic function is advisable during prolonged therapy.</p><p>Prolongation of prothrombin time has been reported rarely in patients receiving amoxicillin/clavulanic acid. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see sec on 4.5 and 4.8).</p><p>In patients with renal impairment, the dose should be adjusted according to the degree of impairment (see sec on 4.2).</p><p>In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria. In patients with bladder catheters, a regular check of patency should be maintained (see sec on 4.9).</p><p>During treatment with amoxicillin, enzymatic glucose oxidase methods should be used whenever testing for the presence of glucose in urine because false positive results may occur with non-enzymatic methods.</p><p>The presence of clavulanic acid in Megamox ES may cause a non-specific binding of IgG and albumin by red cell membranes leading to a false positive Coombs test.</p><p>There have been reports of positive test results using the Bio-Rad Laboratories Platelia <em>Aspergillus </em>EIA test in patients receiving amoxicillin/clavulanic acid who were subsequently found to be free of <em>Aspergillus </em>infection. Cross-reactions with non- <em>Aspergillus </em>polysaccharides and polyfuranoses with Bio-Rad Laboratories .Platelia <em>Aspergillus </em>EIA test have been reported. Therefore, positive test results in patients receiving amoxicillin/clavulanic acid should be interpreted cautiously and confirmed by other diagnostic methods.</p><p>Megamox ES 600 mg/42.9 mg/5 ml powder for oral suspension contains 2.5 mg of aspartame per ml, a source of phenylalanine. This medicine should be used with caution in patients with phenylketonuria.</p><p>Patients with rare heriditary problems of fructose intolerance or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Oral anticoagulants</u>: Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction. However, in the literature there are cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the dose of oral an coagulants may be necessary (see sec on 4.4 and 4.8).</p><p><u>Methotrexate</u>: Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.</p><p><u>Probenecid</u>: Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use of probenecid may result in increased and prolonged blood levels of amoxicillin but not of clavulanic acid.</p><p>The concurrent administration of <u>allopurinol and ampicillin</u> increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. There are no data with AUGMENTIN ES-600 Powder for Oral Suspension and allopurinol administered concurrently.</p><p><u>Oral contraceptive</u>: In common with other broad-spectrum antibiotics, amoxicillin/clavulanate may reduce the efficacy of oral contraceptives</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy</em></strong><strong>:&nbsp;&nbsp; </strong>Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see sec&nbsp;&nbsp; on 5.3). Limited data on the use of amoxicillin/clavulanic acid during pregnancy in humans do not indicate an increased risk of congenital malformations. In a single study in women with preterm, premature rupture of the foetal membrane it was reported that prophylactic treatment with amoxicillin/clavulanic acid may be associated with an increased risk of necrotising enterocolitis in neonates. Use should be avoided during pregnancy, unless considered essential by the physician.</p><p><strong><em>Lactation</em></strong>: Both substances are excreted into breast milk (nothing is known of the effects of clavulanic acid on the breast-fed infant). Consequently, diarrhoea and fungus infection of the mucous membranes are possible in the breast-fed infant, so that breast- feeding might have to be discontinued. The possibility of sensitisation should be taken into account. Amoxicillin/clavulanic acid should only be used during breast-feeding after benefit/risk assessment by the physician in charge.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. allergic reactions, dizziness, convulsions), which may inﬂuence the ability to drive and use machines (see sec on 4.8).</p><p style="text-align:center">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions (ADRs) are diarrhoea, nausea and vomiting.</p><p>The ADRs derived from clinical studies and post-marketing surveillance with Amoxicillin/Clavulanic, sorted by MedDRA System Organ Class are listed in table 1 below.</p><p>The following terminologies have been used in order to classify the occurrence of undesirable effects.</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100 to &lt;1/10)</p><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare (&lt;1/10,000)</p><p>Not known (cannot be estimated from the available data)</p><p>Table 1: Undesirable eﬀacts</p><table border="1" cellspacing="0" cellpadding="0" style="width:737px"><tbody><tr><td colspan="2" style="vertical-align:top; width:734px"><p style="text-align:center"><strong><u>Infections and infestations</u></strong></p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Mucocutaneous candidosis</p></td><td style="vertical-align:top; width:306px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Overgrowth of non-susceptible organisms</p></td><td style="vertical-align:top; width:306px"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:734px"><p style="text-align:center"><strong><u>Blood and lymphatic system disorders</u></strong></p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Reversible leucopenia (including neutropenia)</p></td><td style="vertical-align:top; width:306px"><p>Rare</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Reversible agranulocytosis</p></td><td style="vertical-align:top; width:306px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Haemolytic anaemia</p></td><td style="vertical-align:top; width:306px"><p>Not known</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:738px"><tbody><tr><td style="vertical-align:top; width:430px"><p>Haemolytic anaemia</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Prolongation of bleeding time and prothrombin time<sup>1</sup></p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:735px"><p style="text-align:center"><strong><u>Immune system disorders</u></strong><strong><sup>10</sup></strong></p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Angioneurotic oedema</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Anaphylaxis</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Serum sickness-like syndrome</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Hypersensitivity vasculitis</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:735px"><p style="text-align:center"><strong><u>Nervous system disorders</u></strong></p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Dizziness</p></td><td style="vertical-align:top; width:307px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Headache</p></td><td style="vertical-align:top; width:307px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Reversible hyperactivity</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Convulsions<sup>2</sup></p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:735px"><p style="text-align:center"><strong><u>Gastrointestinal disorders</u></strong></p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Diarrhoea</p></td><td style="vertical-align:top; width:307px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Nausea<sup>3</sup></p></td><td style="vertical-align:top; width:307px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Vomiting</p></td><td style="vertical-align:top; width:307px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Indigestion</p></td><td style="vertical-align:top; width:307px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Antibiotic-associated colitis<sup>4</sup></p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Black hairy tongue</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:735px"><p style="text-align:center"><strong><u>Hepatobiliary disorders</u></strong></p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Rises in AST and/or ALT<sup>5</sup></p></td><td style="vertical-align:top; width:307px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Hepatitis<sup>6</sup></p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:430px"><p>Cholestatic jaundice<sup>6</sup></p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:740px"><tbody><tr><td colspan="2" style="vertical-align:top; width:737px"><p style="text-align:center"><strong><u>Skin and subcutaneous tissue disorders </u></strong><strong><sup>7</sup></strong></p></td></tr><tr><td style="vertical-align:top; width:428px"><p>Skin rash</p></td><td style="vertical-align:top; width:307px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:428px"><p>Pruritus</p></td><td style="vertical-align:top; width:307px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:428px"><p>Urticaria</p></td><td style="vertical-align:top; width:307px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:428px"><p>Erythema multiforme</p></td><td style="vertical-align:top; width:307px"><p>Rare</p></td></tr><tr><td style="vertical-align:top; width:428px"><p>Stevens-Johnson syndrome</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:428px"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:428px"><p>Bullous exfoliative-dermatitis</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:428px"><p>Acute generalised exanthemous pustulosis (AGEP)<sup>9</sup></p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:737px"><p style="text-align:center"><strong><u>Renal and urinary disorders</u></strong></p></td></tr><tr><td style="vertical-align:top; width:428px"><p>Interstitial nephritis</p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:428px"><p>Crystalluria<sup>8</sup></p></td><td style="vertical-align:top; width:307px"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:737px"><p>&nbsp;</p><p><sup>1</sup> See sec on 4.4</p><p><sup>2</sup> See sec on 4.4.</p><p><sup>3</sup> Nausea is more often associated with higher oral doses. If gastrointestinal reactions are evident, they may be reduced by taking amoxicillin/clavulanic acid at the start of a meal.</p><p><sup>4</sup> Including pseudomembranous coli s and haemorrhagic coli s (see sec on 4.4)</p><p><sup>5</sup> A moderate rise in AST and/or ALT has been noted in patients treated with beta-lactam class antibiotics, but the significance of these findings is unknown.</p><p><sup>6</sup> These events have been noted with other penicillins and cephalosporins (see section 4.4).</p><p><sup>7</sup> If any hypersensitivity dermatitis reaction occurs, treatment should be discontinued (see sec on 4.4).</p><p><sup>8</sup> See sec on 4.9</p><p><sup>9</sup> See sec on 4.4</p><p><sup>10</sup> See sec ons 4.3 and 4.4</p><p>&nbsp;</p></td></tr></tbody></table><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><ul><li>Saudi Arabia:</li></ul><p>&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662 Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail:<u> npc.drug@sfda.gov.sa</u></p><p>Website: <u>www.sfda.gov.sa/npc</u></p><ul><li><strong>Other GCC States: </strong>Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs of overdose</u></p><p>Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed (see sec on 4.4).</p><p>Convulsions may occur in patients with impaired renal function or in those receiving high doses.</p><p>Amoxicillin has been reported to precipitate in bladder catheters, predominantly after intravenous administration of large doses. A regular check of patency should be maintained (see sec on 4.4)</p><p><u>Treatment of intoxication</u></p><p>Gastrointestinal symptoms may be treated symptomatically, with attention to the water/electrolyte balance.</p><p>Amoxicillin/clavulanic acid can be removed from the circulation by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Combinations of penicillins, incl. beta-lactamase inhibitors; ATC code: J01CA04.</p><p><u>Mode of action</u></p><p>Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.</p><p>Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.</p><p>Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. Clavulanic acid alone does not exert a clinically useful antibacterial effect.</p><p><u>PK/PD relationship</u></p><p>The time above the minimum inhibitory concentration (T&gt;MIC) is considered to be the major determinant of efficacy for amoxicillin.</p><p><u>Mechanisms of resistance</u></p><p>The two main mechanisms of resistance to amoxicillin/clavulanic acid are:</p><ul><li>Inactivation by those bacterial beta-lactamases that are not themselves inhibited by clavulanic acid, including class B, C and D.</li><li>Alteration of PBPs, which reduce the affinity of the antibacterial agent for the target.</li></ul><p>Impermeability of bacteria or efflux pump mechanisms may cause or contribute to bacterial resistance, particularly in Gram-negative bacteria.</p><p><u>Breakpoints</u></p><p>MIC breakpoints for amoxicillin/clavulanic acid are those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).</p><table border="1" cellspacing="0" cellpadding="0" style="width:677px"><tbody><tr><td rowspan="2" style="vertical-align:top; width:253px"><p>&nbsp;</p><p>Organism</p></td><td colspan="3" style="vertical-align:top; width:422px"><p>Susceptibility Breakpoints (&mu;g/ml)</p></td></tr><tr><td style="vertical-align:top; width:1px"><p>Susceptible</p></td><td style="vertical-align:top; width:1px"><p>Intermediate</p></td><td style="vertical-align:top; width:337px"><p>Resistant</p></td></tr><tr><td style="vertical-align:top; width:253px"><p><em>Haemophilus influenzae</em><strong><sup>1</sup></strong></p></td><td style="vertical-align:top; width:1px"><p>&le; 1</p></td><td style="vertical-align:top; width:1px"><p>-</p></td><td style="vertical-align:top; width:337px"><p>&gt; 1</p></td></tr><tr><td style="vertical-align:top; width:253px"><p><em>Moraxella catarrhalis</em><strong><sup>1</sup></strong></p></td><td style="vertical-align:top; width:1px"><p>&le; 1</p></td><td style="vertical-align:top; width:1px"><p>-</p></td><td style="vertical-align:top; width:337px"><p>&gt; 1</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:679px"><tbody><tr><td style="vertical-align:top; width:217px"><p><em>Staphylococcus aureus </em><strong><sup>2</sup></strong></p></td><td style="vertical-align:top; width:86px"><p>&le; 2</p></td><td style="vertical-align:top; width:94px"><p>-</p></td><td style="vertical-align:top; width:277px"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top; width:217px"><p>Coagulase-negative staphylococci<strong><sup>2</sup></strong></p></td><td style="vertical-align:top; width:86px"><p>&le; 0.25</p></td><td style="vertical-align:top; width:94px"><p>&nbsp;</p></td><td style="vertical-align:top; width:277px"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top; width:217px"><p><em>Enterococcus</em><strong><sup>1</sup></strong></p></td><td style="vertical-align:top; width:86px"><p>&le; 4</p></td><td style="vertical-align:top; width:94px"><p>8</p></td><td style="vertical-align:top; width:277px"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top; width:217px"><p><em>Streptococcus A, B, C, G</em><strong><sup>5</sup></strong></p></td><td style="vertical-align:top; width:86px"><p>&le; 0.25</p></td><td style="vertical-align:top; width:94px"><p>-</p></td><td style="vertical-align:top; width:277px"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top; width:217px"><p><em>Streptococcus pneumoniae</em><strong><sup>3</sup></strong></p></td><td style="vertical-align:top; width:86px"><p>&le; 0.5</p></td><td style="vertical-align:top; width:94px"><p>1-2</p></td><td style="vertical-align:top; width:277px"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top; width:217px"><p>Enterobacteriaceae<strong><sup>1,4</sup></strong></p></td><td style="vertical-align:top; width:86px"><p>-</p></td><td style="vertical-align:top; width:94px"><p>-</p></td><td style="vertical-align:top; width:277px"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top; width:217px"><p>Gram-negative Anaerobes<strong><sup>1</sup></strong></p></td><td style="vertical-align:top; width:86px"><p>&le; 4</p></td><td style="vertical-align:top; width:94px"><p>8</p></td><td style="vertical-align:top; width:277px"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top; width:217px"><p>Gram-positive Anaerobes<strong><sup>1</sup></strong></p></td><td style="vertical-align:top; width:86px"><p>&le; 4</p></td><td style="vertical-align:top; width:94px"><p>8</p></td><td style="vertical-align:top; width:277px"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top; width:217px"><p>Non-species related breakpoints<strong><sup>1</sup></strong></p></td><td style="vertical-align:top; width:86px"><p>&le; 2</p></td><td style="vertical-align:top; width:94px"><p>4-8</p></td><td style="vertical-align:top; width:277px"><p>&gt; 8</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:676px"><p><sup>1</sup> The reported values are for Amoxicillin concentrations. For susceptibility testing purposes, the concentration of Clavulanic acid is ﬁxed at 2 mg/l.</p><p><sup>2</sup> The reported values are Oxacillin concentrations.</p><p><sup>3</sup> Breakpoint values in the table are based on Ampicillin breakpoints.</p><p><sup>4</sup> The resistant breakpoint of R&gt;8 mg/l ensures that all isolates with resistance mechanisms are reported resistant.</p><p><sup>5</sup> Breakpoint values in the table are based on Benzylpenicillin breakpoints.</p></td></tr></tbody></table><p>The prevalence of resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top; width:681px"><p><strong><u>Commonly susceptible species</u></strong></p></td></tr><tr><td style="vertical-align:top; width:681px"><p><u>Aerobic Gram-positive micro-organisms</u></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:685px"><tbody><tr><td style="vertical-align:top; width:682px"><p><em>Enterococcus faecalis</em></p><p><em>Staphylococcus aureus ( </em>methicillin-susceptible)&pound;</p><p><em>Streptococcus agalactiae Streptococcus pneumoniae</em><sup>1</sup></p><p><em>Streptococcus pyogenes </em>and other beta-hemolytic streptococci</p><p><em>Streptococcus viridans </em>group</p><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Capnocytophaga </em>spp.</p><p><em>Eikenella corrodens</em></p><p><em>Haemophilus influenzae</em><sup>2</sup></p><p><em>Moraxella catarrhalis </em></p><p><em>Pasteurella multocida </em></p><p><u>Anaerobic micro-organisms</u></p><p><em>Bacteroides fragilis </em></p><p><em>Fusobacterium nucleatum </em></p><p><em>Prevotella </em>spp.</p></td></tr><tr><td style="vertical-align:top; width:682px"><p><strong><u>Species for which acquired resistance may be a problem</u></strong></p></td></tr><tr><td style="vertical-align:top; width:682px"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecium </em>$</p><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Escherichia coli</em></p><p><em>Klebsiella oxytoca </em></p><p><em>Klebsiella pneumoniae </em></p><p><em>Proteus mirabilis </em></p><p><em>Proteus vulgaris</em></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:688px"><tbody><tr><td style="vertical-align:top; width:685px"><p><strong><u>Inherently resistant organisms</u></strong></p></td></tr><tr><td style="vertical-align:top; width:685px"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter </em>sp.</p><p><em>Citrobacter freundii </em></p><p><em>Enterobacter </em>sp.</p><p><em>Morganella morganii </em></p><p><em>Providencia </em>spp.</p><p><em>Pseudomonas </em>sp.</p><p><em>Serratia </em>sp.</p><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top; width:685px"><p>$ Natural intermediate susceptibility in the absence of acquired mechanism of resistance.</p><p>&pound;All methicillin-resistant staphylococci are resistant to amoxicillin/clavulanic acid</p><p><sup>1</sup><em>Streptococcus pneumoniae </em>that is fully susceptible to penicillin may be treated with this presentation of amoxicillin/clavulanic acid. Organisms that show any degree of reduced suscep bility to penicillin should not be treated with this presenta on (see sec ons 4.2 and 4.4).</p><p><sup>2</sup> Strains with decreased susceptibility have been reported in some countries in the EU with a frequency higher than 10%.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The pharmacokine cs of amoxicillin and clavulanate were determined in a study of 19 pediatric pa ents, 8 months to 11 years, given amoxicillin at dose of 45 mg/kg q12h with a snack or meal. The mean plasma amoxicillin and clavulanate pharmacokinetic parameter values are listed in the following table.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Table 2. Mean (</strong><strong>&plusmn; </strong><strong>SD) Plasma Amoxicillin and Clavulanate Pharmacokinetic Parameter Values Following Administra on of 45 mg/kg of Amoxcillin/clavulanic ES-600 Powder for Oral Suspension Every 12 Hours to Pediatric Patients</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Parameters*</p><p>Active substance(s)</p></td><td style="vertical-align:top"><p>C<sub>max</sub></p></td><td style="vertical-align:top"><p>T<sub>max *</sub></p></td><td style="vertical-align:top"><p><strong>AUC</strong> <sub>(0-24h)</sub></p></td><td style="vertical-align:top"><p>T 1/2</p></td><td style="vertical-align:top"><p>CL/F</p></td></tr><tr><td style="vertical-align:top"><p>(mcg/ml)</p></td><td style="vertical-align:top"><p>(hours)</p></td><td style="vertical-align:top"><p>(mcg.h/ml)</p></td><td style="vertical-align:top"><p>(houurs)</p></td><td style="vertical-align:top"><p>(L/hr/kg)</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p><p>AMX/CA</p><p>600mg/42.9mg/5ml (14:1)</p><p>&nbsp;</p><p>Dosed at 45mg/kg</p><p>Amoxicillin 12- hourly</p></td><td colspan="5" style="vertical-align:top"><p><strong>Amoxicillin</strong></p></td></tr><tr><td style="vertical-align:top"><p>15.7</p><p>&nbsp;</p><p>&plusmn; 7.7</p></td><td style="vertical-align:top"><p>2.0</p><p>&nbsp;</p><p>(1.0-4.0)</p></td><td style="vertical-align:top"><p>59.8</p><p>&nbsp;</p><p>&plusmn; 20.0</p></td><td style="vertical-align:top"><p>1.4</p><p>&nbsp;</p><p>&plusmn; 0.3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.9 &plusmn; 0.4</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Clavulanic Acid</strong></p></td></tr><tr><td style="vertical-align:top"><p>1.7</p><p>&nbsp;</p><p>&plusmn; 0.9</p></td><td style="vertical-align:top"><p>1.1</p><p>&nbsp;</p><p>(1.0-4.0)</p></td><td style="vertical-align:top"><p>4.0</p><p>&nbsp;</p><p>&plusmn; 1.9</p></td><td style="vertical-align:top"><p>1.1</p><p>&nbsp;</p><p>&plusmn; 0.3</p></td><td style="vertical-align:top"><p>1.1</p><p>&nbsp;</p><p>&plusmn; 1.1</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>AMX &ndash; amoxicillin, CA &ndash; clavulanic acid</p><p>*Arithmetic mean &plusmn; standard deviation, except Tmax values which are medians (ranges).</p></td></tr></tbody></table><p>Amoxicillin and clavulanic acid serum concentrations achieved with amoxicillin/clavulanic acid are similar to those produced by the oral administration of equivalent doses of amoxicillin or clavulanic acid alone.</p><p><u>Distribution</u></p><p>About 25% of total plasma clavulanic acid and 18% of total plasma amoxicillin is bound to protein. The apparent volume of distribu on is around 0.3-0.4 l/kg for amoxicillin and around 0.2 l/kg for clavulanic acid.</p><p>Following intravenous administration, both amoxicillin and clavulanic acid have been found in gall bladder, abdominal tissue, skin, fat, muscle tissues, synovial and peritoneal fluids, bile and pus. Amoxicillin does not adequately distribute into the cerebrospinal fluid.</p><p>From animal studies there is no evidence for significant tissue retention of drug-derived material for either component. Amoxicillin, like most penicillins, can be detected in breast milk. Trace quantities of clavulanic acid can also be detected in breast milk (see sec on 4.6).</p><p>Both amoxicillin and clavulanic acid have been shown to cross the placental barrier (see sec on 4.6).</p><p><u>Biotransformation</u></p><p>Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to up to 10 to 25% of the ini al dose. Clavulanic acid is extensively metabolized in man and eliminated in urine and faeces and as carbon dioxide in expired air.</p><p><u>Elimination</u></p><p>The major route of elimination for amoxicillin is via the kidney, whereas for clavulanic acid it is by both renal and non-renal mechanisms.</p><p>Amoxicillin/clavulanic acid has a mean elimination half-life of approximately one hour and a mean total clearance of approximately 25 l/h in healthy subjects. Approximately 60 to 70% of the amoxicillin and approximately 40 to 65% of the clavulanic acid are excreted unchanged in urine during the ﬁrst 6 h a er administra on of single Megamox ES 250 mg/125 mg or 500 mg/125 mg tablets. Various studies have found the urinary excre on to be 50-85% for amoxicillin and between 27-60% for clavulanic acid over a 24 hour period. In the case of clavulanic acid, the largest amount of drug is excreted during the ﬁrst 2 hours a er administraion.</p><p>Concomitant use of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid (see sec on 4.5).</p><p><u>Age</u></p><p>The elimination half-life of amoxicillin is similar for children aged around 3 months to 2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p><p><u>Gender</u></p><p>Following oral administration of amoxicillin/clavulanic acid to healthy males and female subjects, gender has no significant impact on the pharmacokinetics of either amoxicillin or clavulanic acid.</p><p><u>Renal impairment</u></p><p>The total serum clearance of amoxicillin/clavulanic acid decreases proportionately with decreasing renal function. The reduction in drug clearance is more pronounced for amoxicillin than for clavulanic acid, as a higher proportion of amoxicillin is excreted <em>via </em>the renal route. Doses in renal impairment must therefore prevent undue accumulation of amoxicillin while maintaining adequate levels of clavulanic acid (see sec on 4.2).</p><p><u>Hepatic impairment</u></p><p>Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data reveal no special hazard for humans based on studies of safety pharmacology, genotoxicity and toxicity to reproduction.</p><p>Repeat dose toxicity studies performed in dogs with amoxicillin/clavulanic acid demonstrate gastric irritancy and vomiting, and discoloured tongue.</p><p>Carcinogenicity studies have not been conducted with Megamox ES or its components.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp; Xanthan Gum</p><p>-&nbsp; Succinic Acid micronized</p><p>-&nbsp; Colloidal Silicon Dioxide</p><p>-&nbsp; Predried nutra sweet-aspartam treated</p><p>-&nbsp; Predried hydroxypropyl methyl cellulose</p><p>-&nbsp; Orange Powder Flavor</p><p>-&nbsp; Predried Silicon Dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dry powder 2 years.
The reconstituted suspension is stable for 10 days when stored at 2 – 8 °C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p><p>The reconstituted suspension should be stored in a refrigerator (2 &ndash; 8 &deg;C) and used within 10 days.</p><p>Keep in the original container. Keep the container tightly closed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glass bo le Amber 125 ml,28mm induc on plas c CRC Caps.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At time of dispensing, the dry powder should be reconstituted to form an oral suspension, as detailed below:</p><p>After opening the bottle remove the membrane carefully and completely and discard before reconstituting the product. Fill the bottle with water to just below the mark on the label and shake well at once. Then add water exactly to the mark and shake vigorously again.</p><p>Shake the bottle well before every withdrawal.</p><p>After reconstitution the ready-for-use suspension is off-white.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries (JPI) 
Riyadh, Saudi Arabia
11666 Riyadh, P.O.Box 106229

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01 January 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>